Exciting Developments in Sickle Cell Program
Congratulations to investigators in our Sickle Cell Program for a number of exciting achievements!
First, we are thrilled to announce that Shuaiying Cui has been awarded a prestigious Doris Duke Sickle Cell Disease/Advancing Cures award for his groundbreaking work on LSD1 inhibitors. The award will support his research over the next several years, as he further develops this novel approach to inducing fetal hemoglobin in sickle cell patients.
Additionally, after a highly competitive process, our Sickle Cell Program has been selected as a key site for a national registration study of crizanlizumab in patients with sickle cell disease. Treatment with crizanlizumab was recently shown, in a study published in the New England Journal of Medicine, to be a highly promising approach for decreasing vaso-occlusive crises.
We are very much looking forward to participating in this study, and to be able to offer this promising new treatment to our patients!